ALK and non-small cell lung carcinoma: Ceritinib is approved for the treatment of patients with Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) but can also inhibit the insulin receptor (INSR), the insulin-like growth factor 1 receptor (IGF1R) and ROS proto-oncogene 1 (ROS1) [11].